DNA sequencer Helicos BioSciences aims to raise $81M in IPO
Helicos BioSciences, a Cambridge, Mass., developer of high-speed DNA and RNA sequencing technology, hopes to raise as much as $81 million in an initial offering, according to an SEC filing.
The company said in the filing that it hopes to offer 5.4 million shares at $13 to $15 per share. The IPO market for biotechs has been tepid recently, and several companies have recently either lowered their asking price or withdrawn their proposed offering altogether.
Helicos’ technology is designed to sequence single molecules of DNA or RNA at extremely high speeds, in hopes of making it economical to scan entire human, animal or pathogen genomes in real time.
Next Story: Combinent BioMedical Systems, a drug-delivery company, pulls in $3M
Previous Story: Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.